Medical prevention of respiratory-synchitic viral infection in the present and future
Open Access
- 28 December 2024
- journal article
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 8(144),p. 95-106
Abstract
Respiratory syncytial virus (RSV) is one of the most common respiratory viral agents and the main cause of lower respiratory tract infections in children and the elderly that have an unfavorable outcome. Unfortunately, current national recommendations for the treatment of patients with RSV infection (RSVI) are limited mainly to pathogenetic and symptomatic therapy. Instead, scientists are focusing on the development of new drugs that inhibit the activity of various viral proteins and surface receptor molecules of respiratory tract epithelial cells. Aim - to provide an overview of the main current and future strategies for RSVI prevention. The drug prophylaxis of RSVI, which is recommended in the form of passive and active immunization, is highly effective. Passive immunization is recommended for children, while vaccination is mainly indicated for pregnant women and the elderly. For passive immunization in children, medications containing recombinant monoclonal RSV-neutralizing antibodies, such as palivizumab and nircevimab, are used. Palivizumab is administered intramuscularly once a month throughout the RSV season. At the same time, nirsevimab requires only a single injection to achieve the preventive effect. The duration of the preventive effect of nirsevimab is due to the modification of the mAb molecule, which significantly increases the half-life of the mAb. For children in the first six months of life whose mothers were vaccinated during pregnancy, it is recommended to be vaccinated with Abrisvo vaccine during the period of increased incidence of RSVI. For the prevention of RSVI in the elderly, it is recommended to use Arexvie and Abrisvo vaccines, and for pregnant women - the bivalent subunit Abrisvo vaccine. It is believed that the introduction of new RSVI preventive strategies will significantly reduce both the incidence of the disease and the risk of adverse outcomes from this infection. The authors declare no conflict of interest.Keywords
This publication has 76 references indexed in Scilit:
- Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to DatePediatric Drugs, 2023
- Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virusHealth Science Reports, 2023
- Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infectionCochrane Database of Systematic Reviews, 2023
- Review and Update of Active and Passive Immunization Against Respiratory Syncytial VirusBioDrugs, 2023
- Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and ChildrenJAMA Network Open, 2023
- Nirsevimab: First ApprovalDrugs, 2022
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in childrenCochrane Database of Systematic Reviews, 2021
- Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in ChildrenInfectious Diseases and Therapy, 2018
- Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c miceAntiviral Research, 2014
- Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various IndicationsArchives of Pediatrics & Adolescent Medicine, 2011